Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Dermabacter

ABSTRACT: The Genome sequencing and assembly of Dermabacter spp.

PROVIDER: PRJNA450221 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7031346_1.fastq.gz	Fastqsanger.gz
	SRR7031346_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 2 of 2

Similar Datasets

Dermabacter

Project description:The Genome sequencing and assembly of Dermabacter spp.

| PRJNA450221 | ENA

Dermabacter hominis 1368

Project description:Dermabacter hominis 1368 Genome sequencing and assembly

| PRJNA235370 | ENA

Dermabacter

Project description:Dermabacter sp. overview

| PRJNA169591 | ENA

Dermabacter hominis

Project description:Dermabacter hominis overview

| PRJNA235966 | ENA

Dermabacter jinjuensis strain:32T

Project description:Dermabacter jinjuensis strain:32T Genome sequencing

| PRJNA407870 | ENA

Dermabacter hominis NBRC 106157

Project description:Dermabacter hominis NBRC 106157 genome sequencing project

| PRJDB1334 | ENA

Dermabacter sp. Marseille-Q3180

Project description:Dermabacter sp. Marseille-Q3180 genome

| PRJEB52557 | ENA

Project description:Dermabacter indicis genome

| PRJEB10922 | ENA

Multiazole resistance in clinical and environmental fungal isolates

Project description:Whole genome sequencing of SYBARIS Aspergillus spp. known to be multi-drug resistant and difficult to treat. Aim of this experiment is to investigate the genetic basis of susceptibility to disease and elucidate molecular mechanisms of drug resistance in these strains.

2016-04-30 | E-SYBR-1 | biostudies-arrayexpress

A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer.

Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS). Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).

| 2533916 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data